Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Total Current Liabilities data on file, last reported at $80.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 19.57% year-over-year to $80.9 million; the trailing twelve-month figure through Mar 2026 stood at $80.9 million (up 19.57% YoY), and the FY2025 full-year result was $77.8 million, up 14.99% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $80.9 million, up from $77.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $80.9 million in Q1 2026 and bottomed at $41.5 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $56.5 million (2023), against an average of $59.6 million.
• The widest annual swing landed in 2022, when Total Current Liabilities soared 50.36%; it then fell 2.26% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $49.0 million in 2022, then grew by 14.65% to $56.2 million in 2023, then gained by 20.34% to $67.7 million in 2024, then gained by 14.99% to $77.8 million in 2025, then increased by 4.02% to $80.9 million in 2026.
• The last three Total Current Liabilities figures came in at $80.9 million (Q1 2026), $77.8 million (Q4 2025), and $75.2 million (Q3 2025), per Business Quant data.

Peer Comparison